TY - JOUR
T1 - Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer
T2 - Biomarker for treatment selection exclusion or inclusion?
AU - Leibrand, Crystal R.
AU - Price, Douglas K.
AU - Figg, William D.
N1 - Publisher Copyright:
© 2016 Taylor & Francis Group, LLC.
PY - 2016/5/3
Y1 - 2016/5/3
N2 - Currently there are no molecular biomarkers used to help guide treatment selection for those patients with castration-resistant prostate cancer. A recent study published in JAMA Oncology (Antonarakis et al.) presents evidence supporting the potential use of androgen receptor splice variant 7 as a biomarker for optimal treatment selection in this population.
AB - Currently there are no molecular biomarkers used to help guide treatment selection for those patients with castration-resistant prostate cancer. A recent study published in JAMA Oncology (Antonarakis et al.) presents evidence supporting the potential use of androgen receptor splice variant 7 as a biomarker for optimal treatment selection in this population.
KW - Androgen receptor; prostate cancer; splice variants
UR - http://www.scopus.com/inward/record.url?scp=84963603681&partnerID=8YFLogxK
U2 - 10.1080/15384047.2016.1156274
DO - 10.1080/15384047.2016.1156274
M3 - Article
C2 - 26985596
AN - SCOPUS:84963603681
SN - 1538-4047
VL - 17
SP - 467
EP - 469
JO - Cancer Biology and Therapy
JF - Cancer Biology and Therapy
IS - 5
ER -